SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the company begins testing fully autonomous robotaxis in Austin, generating excitement and debate within the community about the implications for the EV and ride-sharing markets. Bullish sentiment is fueled by expectations of a "Santa Claus rally" and analysts setting ambitious price targets, while bears point to valuation concerns and potential market corrections. Discussions also include comparisons with competitors and speculation on future developments in AI and autonomous driving.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending as traders react to overnight futures movement and brace for upcoming jobs data, with some suggesting the market is overvalued and due for a correction. Community chatter highlights concerns about potential manipulation and the impact of the Japanese Yen carry trade. Others are focused on sector rotation and upcoming earnings reports.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending downwards, with community members actively debating whether this decline represents a buying opportunity or the start of a longer-term downtrend. The discussions encompass broader concerns about an AI bubble, the impact of potential interest rate hikes, and sector-specific news impacting data center stocks. Some investors express frustration with the stock's volatility and question the company's fundamentals, while others remain bullish, citing long-term growth potential and strategic partnerships.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

Dog (Bitcoin) is trending as community members highlight its position as a leading meme coin on the Bitcoin network. Bullish sentiment is fueled by the growth of the $DOG treasury and the belief that it will onboard future Bitcoin users. Some users speculate on potential exchange listings and highlight the strength of the $DOG army.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amid concerns about potential market crashes and reactions to upcoming economic data, like the jobs report, creating uncertainty. Community discussions revolve around the possibility of a Santa rally versus deeper market corrections, with some traders expressing frustration over perceived market manipulation. Broader economic fears, including concerns about debt markets and potential impact from international monetary policy, are also contributing to the cautious sentiment.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom ($AVGO) is trending downwards as investors express concerns about AI revenue translation and margin impacts following the latest earnings report. The community is debating whether the drop is an overreaction or the start of a larger correction, with some pointing to analyst target prices and oversold indicators suggesting a rebound, while others believe further declines are ahead.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Despite a strong AI narrative and positive news regarding a deal with Runway, $CRWV is experiencing volatility, influenced by sector-wide concerns stemming from $ORCL and $AVGO. The community is debating whether this dip presents a buying opportunity or signals deeper issues related to debt and potential insider selling, with some traders pointing to oversold conditions and potential for a significant rebound.

nLIGHT, Inc. engages in the provision of semiconductor and fiber lasers for aerospace and defense, industrial, and microfabrication applications. It operates through the Laser Products and Advanced Development segments. The Laser Products segment designs, manufactures, and sells a range of semiconductor lasers and fiber lasers that are typically integrated into laser systems or manufacturing tools built by customers. The Advanced Development segment focuses on research, design, and prototyping of next-generation laser technologies, leveraging expertise in laser technology, development, beam control, and advanced optics. The company was founded by Scott H. Keeney, Mark DeVito, and Jason Farmer in June 2000 and is headquartered in Camas, WA.

nLIGHT Inc

nLIGHT ($LASR) is trending as investors discuss its potential role in defense contracts, particularly the "Golden Dome" initiative, while noting strong Aerospace & Defense revenue growth. Community members highlight the company's technical capabilities in laser technology and speculate on significant upside potential if key contracts materialize. Some traders are watching for a breakout, while others cite the stock's strong year-to-date performance and potential for further gains.

AMC Robotics Corp. engages in developing and deploying AI-enabled robotics and smart security solutions, especially for warehouse automation, enterprise security, robotics patrol/incident-response and logistics automation. The company is headquartered in New York, NY.

AMC Robotics Corp.

AMCI is trending due to its significant after-hours gains and high trading volume, sparking discussions about a potential short squeeze. The community is actively debating realistic opening prices and whether it can repeat the performance of similar stocks, with some pointing to its small float and others cautioning about a potential pump and dump. The stock's connection to the robotics sector and AI is also fueling interest, despite concerns about its underlying financials and business model.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending downwards as investors discuss a potential unwind of AI infrastructure investments following news from Oracle and Broadcom. The community is actively debating the extent of the drop, with some viewing it as a buying opportunity while others express concern about technical damage to the stock's chart. Despite the negative price action, some bulls highlight long-term contracts and potential for hyperscaler partnerships.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should You Invest in the iShares Biotechnology ETF (IBB)?

<ul class="summary-bullets"><li>Super Micro's headwinds stemming from AI-bubble fears contrast with improving compliance, new Nvidia-powered products, and a more reasonable valuation.</li><li>Moderna continues to struggle post-pandemic, with weak fundamentals, no new blockbusters, and higher regulatory scrutiny weighing on its pipeline.</li><li>Analysts see greater upside for Super Micro than Moderna, while retail sentiment remains cautious toward both stocks.</li></ul>Investing in heavily shorted stocks isn't for the faint-hearted. While they can offer meaningful upside, that potential comes with heightened volatility and elevated risk. More often than not, they are shorted for legitimate reasons. But if the sentiment flips, these stocks can deliver explosive gains. The most-shorted S&amp;P 500 list currently includes two names that won't surprise many investors.&nbsp;Moderna — the biopharma that, along with Pfizer, led the COVID-19 vaccine race — rode a historic wave of demand during the pandemic. But as the outbreak faded and vaccine sales collapsed, the company's fundamentals have come under pressure despite efforts to sustain momentum with second-generation and combination shots. The company is still searching for its next blockbuster therapy.Super Micro Computer, Inc. (SMCI), which rode the artificial intelligence mania, selling AI servers, was once touted as a promising opportunity. The company, however, ran into rough weather in 2024 amid accusations of accounting issues, delays in filing of financial reports, and&nbsp;attacks from short-sellers.Since peaking at $122.90 on March 8, 2024, the stock has traded broadly downward for the rest of the year. Super Micro's addition to the S&amp;P 500 provided a boost, but it failed to reignite the uptrend. Notably, the company was removed from the Nasdaq 100 just five months after its inclusion in the tech index.<h2 class="st-heading-2">Stock Returns This Year</h2>As Super Micro became compliant with the listing requirements for timely quarterly reporting, buyers returned to the stock. The<a href="https://stocktwits.com/symbol/SMCI">&nbsp;SMCI stock</a> also benefited from the company's new offerings involving Nvidia's newest high-performance chips and its positive long-term outlook. Its near-term underperformance raised concerns among investors.&nbsp;After rising through the first quarter, Super Micro's stock pulled back and hit a low in mid-November and has been consolidating since.<a href="https://stocktwits.com/symbol/MRNA">Moderna's stock</a> was on a steady downward trajectory this year, barring occasional consolidation moves.<img src="https://news.stocktwits-cdn.com/MRNA_SMCI_stock_returns_png_dd55f22501.webp" alt="MRNA-SMCI stock returns.png">Source: Koyfin<h2 class="st-heading-2">Elevated Short Bets&nbsp;</h2>According to Koyfin, the short interest for Super Micro peaked in April (19.60%) before reducing to 14.70% currently. Moderna's short interest, though off its May peak of 17.40%, has declined by less than one percentage point.<img src="https://news.stocktwits-cdn.com/MRNA_SMCI_short_interest_png_9af30dca45.webp" alt="MRNA-SMCI-short interest.png">Source: Koyfin<h2 class="st-heading-2">Time To Revisit?</h2>Super Micro now trades at a relatively reasonable valuation (in terms of the forward price-earnings (P/E) multiple versus the tech sector and its peak multiple).<img src="https://news.stocktwits-cdn.com/SMCI_Forward_PE_png_d98fc94770.webp" alt="SMCI_Forward_PE.png">Source: Fiscal.aiModerna, on the other hand, trades at a much higher price-to-sales (P/S) multiple than it did last July. Since Moderna is projected to report losses over the next year, the P/E ratio isn't applicable.<img src="https://news.stocktwits-cdn.com/MRNA_Forward_PS_png_794682e423.webp" alt="MRNA_Forward_PS.png">Source: Fiscal.aiAccording to Koyfin-compiled consensus analysts' stock price targets for the companies,&nbsp; estimates, Super Micro has an upside potential of 39% versus 23% for Moderna.&nbsp;Super Micro has an equal share of analysts who are bullish and neutral on the stock. Meanwhile, more analysts are on the sidelines of Moderna (15 of the 22 analysts covering the stock).On Stocktwits, retail traders are 'bearish' on Super Micro as of early Thursday, while Moderna elicited 'neutral' sentiment.For Super Micro, simmering AI bubble fears could remain an overhang on the stock. Still, if the company can execute its plans and leverage its partnership with Nvidia, the stock could see a reversal in fortunes. Moderna, meanwhile, remains a "show-me" story as it has to prove the mettle of the rest of its pipeline. Moderna also faces regulatory uncertainty as the FDA applies heightened scrutiny to new vaccines and therapeutics, adding another layer of risk to its pipeline.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:<a href="https://stocktwits.com/news-articles/markets/equity/powell-didn-t-surprise-how-retail-traders-are-positioning-after-fed-s-rate-cut/cLIx7TYREn2">&nbsp;Powell Didn't Surprise — But Markets Might: How Retail Traders Are Positioning After Fed's Rate Cut</a>

 Traders work on the floor of the New York Stock Exchange (NYSE) on December 02, 2025 in New York City. After losing over 400 points on the first day of December, the market began to recover with the Dow up over 120 points in morning trading. 

Moderna And Super Micro Top S&P 500 Short Interest List — Are They Ripe For A Squeeze?

Investors remain divided on Moderna and Super Micro as heavy short interest reflects skepticism, yet recent catalysts suggest both names could still deliver unpredictable, sentiment-driven swings.

Equity

Inside the Recent Strength in Biotech ETFs 

Biotech strength is back, with IBB, PBE, FBT, CANC and HELX climbing as cheaper valuations, rate-cut hopes, FDA approvals and strong deal activity fuel biotech gains.



Biotech ETFs Hovering Around a 52-Week: Here's Why 

Biotech is back! Regulatory tailwinds, cheaper valuations, and Fed cut hopes are boosting ETFs like XBI and IBB. Is the rebound just starting?

Biotech ETFs Bounce Back in 2025: Here's Why  

Biotech ETFs rally. IBB, ARKG, SBIO, BBC, CANC and BBP soar as Fed rate cut optimism, FDA approvals, deals and cheaper valuations drive the space in 2025.

Health and Human Services Secretary Robert F. Kennedy Jr. will appear before the Senate Finance Committee on Sept. 4 to discuss U.S. President Donald Trump’s healthcare agenda.Chairman Mike Crapo said the hearing will focus on “the Department of Health and Human Services’ Make America Healthy Again actions to date and plans moving forward,” Reuters&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/kennedy-testify-before-senate-panel-health-agenda-2025-08-28/">reported</a>.The session comes after the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/cdc-chief-susan-monarez-pushed-out-after-weeks-on-job-as-rfk-jr-overhauls-agency-she-s-fighting-back/chsCsP4Rdli">White House dismissed CDC Director Susan Monarez</a> on Wednesday, less than a month into her tenure. An associate said Monarez was fired after resisting vaccine policy changes advanced by Kennedy that she believed contradicted scientific evidence.&nbsp;Hours later, three senior officials — Chief Medical Officer Debra Houry, National Center for Immunization and Respiratory Diseases Director Demetre Daskalakis, and National Center for Emerging and Zoonotic Infectious Diseases Director Daniel Jernigan — resigned and were&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/legal/litigation/fired-cdc-director-clashed-with-kennedy-on-vaccine-policy-2025-08-28/">reportedly</a> escorted from the Atlanta campus.&nbsp;CDC staff, many wearing green shirts and ribbons as a sign of support, applauded them as they departed.Richard Besser, former acting CDC director, said Monarez told him she would not take any action that was illegal or “flew in the face of science,” and she refused to dismiss her leadership team without cause.&nbsp;The three departing officials said they resigned over anti-vaccine policies and misinformation promoted by Kennedy and his team. Daskalakis said, “I’m a doctor. I took the Hippocratic oath that said, ‘First, do no harm.’ I believe harm is going to happen, and so I can’t be a part of it.”Since taking office this year, Kennedy has fired the CDC’s vaccine advisory panel and replaced it with anti-vaccine activists and other advisers.&nbsp;He has made false claims about vaccines and launched an investigation into autism rates that he has linked, without evidence, to “environmental toxins.”&nbsp;The CDC has since dropped its recommendation that pregnant women be vaccinated against COVID and narrowed its guidance for children with health complications.White House spokeswoman Karoline Leavitt said Monarez was dismissed because she did not align with the president’s mission. “She said she would [resign], and then she said she wouldn’t, so the president fired her,” Leavitt said.&nbsp;Kennedy declined to comment on the specifics of the departures but told&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.foxnews.com/media/rfk-jr-warns-cdc-in-trouble-promises-fixes-director-refuses-step-down">Fox News</a>, “The agency is in trouble, and we need to fix it and we are fixing it. And it may be that some people should not be working there anymore.”&nbsp;Deputy HHS Secretary Jim O’Neill was named interim director of the CDC.Monarez’s dismissal is one of several recent moves by Trump to remove Senate-confirmed officials, including Federal Reserve Governor Lisa Cook and Surface Transportation Board member Robert Primus.On Stocktwits, retail sentiment was ‘bearish’ with ‘low’ message volume for both the iShares Biotechnology ETF (IBB) and the Health Care Select Sector SPDR Fund (XLV).While&nbsp;<a href="https://stocktwits.com/symbol/XLV">XLV</a> has been flat so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/IBB">IBB</a> has risen 4.6% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Health and Human Services Secretary Robert F. Kennedy Jr. speaks during a cabinet meeting with U.S. President Donald Trump on August 26, 2025 in Washington, DC. (Photo by Chip Somodevilla/Getty Images)

CDC Turmoil Escalates: Kennedy To Testify In Senate After Director Fired, Senior Officials Quit

The White House's move to oust Susan Monarez and the wave of senior CDC resignations have spotlighted deep divisions over vaccine policy and raised fresh questions about the administration’s healthcare agenda.

U.S. Centers for Disease Control and Prevention Director Susan Monarez has left the agency less than a month after being sworn in, amid the resignation of four senior officials&nbsp;who also resigned over vaccine policy tensions.Monarez’s attorneys said she is challenging her ouster, accusing HHS Secretary Robert F. Kennedy Jr. of targeting her for rejecting “unscientific directives,” Reuters&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/us-cdc-chief-exits-after-weeks-role-three-top-officials-resign-2025-08-27/">reported</a>.&nbsp;“Dr. Monarez has neither resigned nor received notification from the White House that she has been fired, and as a person of integrity and devoted to science, she will not resign,” lawyers Mark S. Zaid and Abbe David Lowell said.The U.S. Department of Health and Human Services' account on X shared a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/HHSGov/status/1960818490614415869">post</a> about Monarez's exit, saying: "We thank her for her dedicated service to the American people. @SecKennedy has full confidence in his team at @CDCgov who will continue to be vigilant in protecting Americans against infectious diseases at home and abroad."CDC Chief Medical Officer Debra Houry and Immunization Center Director Demetre Daskalakis have resigned, citing the rise in health misinformation, attacks on science, and budget cuts.&nbsp;Infectious Diseases Director Daniel Jernigan and Public Health Data Director Jen Layden also stepped down. Houry wrote that overstated risks and misinformation have fueled record measles cases and even a violent attack on the CDC.The White House’s 2026 budget proposed cutting CDC funding by $3.6 billion, while Kennedy had already eliminated 2,400 jobs and rehired 700. Daskalakis said he could not serve amid the “ongoing weaponizing of public health.”The CDC has faced mounting strain under Kennedy, including a shooting at its Atlanta headquarters. Former CDC official Fiona Havers called the latest resignations “devastating,” saying the departed leaders had shielded scientists from political attacks.Kennedy has rolled back vaccine policies, withdrawing COVID shot recommendations for children and pregnant women, and firing all members of the CDC vaccine advisory panel in June, replacing them with hand-picked advisers, including vaccine skeptics.&nbsp;On Wednesday, he announced further changes to COVID-19 vaccine eligibility and stated that autism policy announcements are expected in September.Monarez, a federal scientist, was confirmed on July 29 after being nominated by U.S. President Trump and sworn in by Kennedy on July 31. She succeeded Trump’s withdrawn pick, former congressman and vaccine critic Dave Weldon.&nbsp;On Stocktwits, retail sentiment was bearish for both the iShares Biotechnology ETF (IBB) with normal message volume, and the Health Care Select Sector SPDR Fund (XLV) with low message volume.So far this year,&nbsp;<a href="https://stocktwits.com/symbol/IBB">IBB</a> has gained 4.9%, while&nbsp;<a href="https://stocktwits.com/symbol/XLV">XLV</a> has increased by 0.4%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Monarez is a health scientist with a Ph.D. in microbiology and immunology who previously served as the Deputy Director of the Advanced Research Projects Agency for Health. (Photo by Kayla Bartkowski/Getty Images)

CDC Chief Susan Monarez Pushed Out After Weeks On Job As RFK Jr. Overhauls Agency — She’s Fighting Back

The sudden leadership shake-up at the CDC deepens turmoil inside the agency, where multiple senior officials have also resigned over vaccine policy disputes with Health Secretary Robert F. Kennedy Jr.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

US Food and Drug Administration Commissioner Marty Makary said he’s “taking a hard look” at whether Sarepta Therapeutics’ gene therapy, Elevidys, should remain on the market, following recent patient deaths involving the treatment.&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="http://stockwits.com/symbol/SRPT">Sarepta’s stock</a> plummeted more than 26% in midday trade on Friday. However, on Stocktwits, retail sentiment around the company remained in ‘extremely bullish’ territory amid ‘extremely high’ levels of chatter.A separate&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-request-sarepta-stop-all-shipments-gene-therapy-elevidys-source-says-2025-07-18/#:~:text=The%20FDA's%20request%20follows%20the,condition%20called%20Duchenne%20muscular%20dystrophy.">report</a> by Reuters said that the FDA plans to request Sarepta to stop all shipments of Elevidys voluntarily.Makary’s comments during an&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-07-18/fda-is-investigating-if-sarepta-s-elevidys-should-stay-on-market">interview</a> with Bloomberg come after the company on Thursday disclosed a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/sarepta-draws-wall-street-ire-after-third-patient-death-this-year/ch8kMF7R5qY">third patient death</a> in a clinical trial involving a different experimental gene therapy that uses a similar viral delivery system.&nbsp;A company spokesperson&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-07-18/sarepta-says-another-patient-died-after-receiving-gene-therapy">told</a> Bloomberg that a 51-year-old patient died of acute liver failure last month in an early-stage trial of a gene therapy to treat limb-girdle muscular dystrophy.The FDA had already been investigating two earlier deaths linked to Elevidys.The growing number of fatalities is raising questions about the future of Sarepta’s therapies and the regulatory path for gene treatments that use adeno-associated viral (AAV) vectors. Elevidys, which was granted accelerated approval in 2023 for Duchenne muscular dystrophy, has remained on the market under post-approval study requirements.Bloomberg also reported that the latest death resulted in an unusually tense exchange between analysts and Sarepta executives on a Friday call. The same group of analysts reportedly had a call with the company earlier this week about the future of Elevidys, but the firm failed to disclose the third patient death. On Friday, two of the analysts asked executives whether the company was keeping any other fatalities undisclosed.“We are historically a very transparent organization,” said Sarepta CEO Douglas Ingram, according to the report, adding that the company didn’t disclose the third patient death earlier because “it was neither material nor central” to what was being discussed.&nbsp;Sarepta’s stock is down 88% year-to-date and nearly 90% over the past 12 months.Get updates to this developing story directly on Stocktwits.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/grubhub-owner-wonder-reportedly-in-talks-for-500-m-debt-refinancing/ch8kHoKR5qp">Grubhub Owner Wonder Reportedly In Talks For $500M Debt Refinancing</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Sarepta Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

FDA Is Reportedly ‘Taking A Hard Look’ To Evaluate Whether Sarepta’s Gene Therapy Elevidys Should Remain On The Market

The FDA had already been investigating two earlier deaths linked to Elevidys.

Current Price	$169.38
Prev Close	$169.42
Open	$169.65
Dividend Yield	N/A
50-Day Moving Average	$161.50
Beta	N/A
Avg. Volume	2.68M
PE Ratio	N/A

52-Week High	$174.40
52-Week Low	$107.43
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

IBB
iShares Biotechnology ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IBB News

IBBiShares Biotechnology ETF